The US playbook: what the winners teach us

LessonsThe graveyard, and what killed them

Dead or zombie by mid-2026: Eargo, Lexie and Go Hearing (parent LXE winding down, support ends Sept 15), Sony’s CRE line (partnership not renewed), Jabra Enhance Plus (killed three weeks after Apple’s hearing-aid announcement), Nuheara/HP (administration), Lucid Hearing (offline, lost Sam’s Club), and Sonova is divesting the entire Sennheiser consumer division. Five repeating death traits:

• Premium price with no care moat — the $700–$1,100 gadget middle that Apple crushed.
• VC-scale customer acquisition against small tickets. Eargo/Lexie burned $100M+ buying customers a $299–$999 sale could never repay. hear.com’s internet-scale funnel only pencils at $2,000–$5,000 prescription tickets.
• Earbud form factor without an ecosystem — competing on Apple’s home turf at higher prices.
• Borrowed brands with misaligned owners — Sony, HP and Bose-powered Lexie all died overnight when the licensing partner stopped caring.
• App-dependence as liability — LXE’s wind-down orphans app-dependent devices; buyers now actively ask “will this company exist in three years?” Our answer must be: the clinic can fit and adjust the device even if every app disappears.

ModelsThe survivors, and why they live

Scroll the table sideways on small screens.

• Care attached to hardware, always. The only care-less survivors are Apple (ecosystem) and sub-$150 players (price resets expectations). Everyone else bundles humans.
• Borrowed credibility, cheaply bought. HearAdvisor lab submission → Expert Choice award → NCOA/Soundly/HearingTracker rankings → audiologist YouTube reviews. It costs a lab fee, not an ad budget — and Cearvol has already run most of this ladder in the US.
• Trial generosity is the trust currency. 45 days is the category floor; Jabra’s 100 days and Costco’s 180 are the trust leaders. Protection-plan upsells (MDShield, AudienCare) add recurring revenue.
• Annual launch cadence timed to CES keeps press coverage and “best of” list placements fresh.

The machinehear.com: the one funnel that conquered this market

Founded 2012 in Berlin, acquired by the Siemens hearing spinoff, now the demand engine of WS Audiology (€2.6B revenue). The model in one sentence: they own the customer end-to-end — ads, quiz, a 40-minute phone consult, the sale, financing — and outsource only the physical fitting to ~2,000 partner clinics, who join free, get exclusive territories, and are paid for their clinical time. One million phone consultations a year. And critically for us: hear.com already operates in Canada with 200+ partner clinics — they are simultaneously our proof-of-concept and our competitor for clinic attention.

The funnel, step by step

• Every ad leads to a qualification quiz, not a store. “Check if you qualify for a 45-day no-risk trial” — eight emotional taps (who is it for, why now, what are you looking forward to, a covert budget question), no audiogram. The word “qualify” does double duty: risk reversal plus exclusivity.
• A phone call within 15 minutes from a commissioned “hearing expert” converts anxious first-timers no e-commerce cart could, and pre-qualifies the lead so partner clinics’ show and close rates stay high — which is what keeps clinics loyal.
• The offer is the trial, not the product. 45-day money-back on every asset; prices always framed monthly (“$112/mo”, “$2.70 per day”); a financing waterfall that approves down to ~520 credit scores.
• They never publish prices — “the best way to get precise pricing is a free consultation.” Rebranding Signia hardware as “Horizon” kills price comparison.

Why it wins where cheap-device ventures died

They inverted the clinic incentive. Everyone else asks clinics to sell cheaper hardware; hear.com feeds clinics pre-sold patients for free and pays for their clinical time. Joining is pure upside. Their partner-recruitment page is the single most relevant artifact for our trade site — headline “Become a partner and grow your business with new customers,” threat framing (Costco, online), “keep your independence,” territory scarcity (“we reserve specific regions — spots are limited”), and a named human with a direct phone number as the CTA.

EvidenceThe clinic channel works — and we finally have the receipts

The fear that kills this conversation in every clinic is cannibalization: “why would I sell a $400 device when I sell $4,000 pairs?” The US data answers it directly:

• Mass Eye & Ear (peer-reviewed, selling entry devices in-clinic since 2017): entry devices stayed at 1% of units sold — no cannibalization. 38% of entry buyers paid for fitting services on top. Return rate was higher (17%) — but 66% of returners bought prescription aids. Even the failures convert upward.
• Washington University clinic (Michael Valente): stocked a ~$200-invoice entry aid, dispensed with real-ear measurement, and found 93% of counseled patients still chose the premium bundled aids. The affordable shelf worked as a price anchor that made the $4,000 recommendation feel considered rather than coerced. His mantra: “They entered your house — keep them in your house.”
• MarkeTrak 25: prescription adoption rose from 30% to 39% during the OTC era; cost remains the #1 reason patients walk; a $250 device would be affordable to over 90% of adults with hearing loss. The walkout is real, enormous, and currently monetized by nobody.
• Optometry already measures this: average optical capture is ~50–60% — roughly 45% of dispensing revenue walks out the door. Their fix is ours: the doctor recommends from the chair, tiered good/better/best pricing so the budget buyer has an in-house option, and capture rate tracked as a KPI.
• The “professional exclusive” template (SkinCeuticals, Thorne, veterinary diets, Philips Zoom): restricted distribution + clinical framing + the professional’s recommendation converts a low-ticket item from retail clutter into professional care. MAP enforcement is not fine print — it IS the pitch, to both the clinic and the patient: “your patient cannot shop your recommendation against you.”

What independents expect from a supplier (the table stakes)

Forty years of manufacturer behaviour trained clinics to expect: a named rep who answers the phone, free demo units, a small sale-or-return starter kit, training, co-op marketing money or done-for-you materials, easy ordering, and generous returns with the clinic held harmless. Buying groups (Audigy, CQ Partners, Starkey Alliance) win independents with patient flow and business help, not discounts — and one structural gift: many clinics are locked into purchase-concentration deals with one manufacturer, but a non-competing sub-$500 tier doesn’t count against prescription volume commitments. We slip through where another prescription line can’t.

Swipe fileThe ads: angles, formats, offers

The angles that dominate (with the words they use)

• Tech legitimacy. hear.com’s advertorial is the category’s best single swipe: skeptic-acknowledging cold open, a named audiologist quote (“They go from struggling to hear to ‘wow’ in seconds”), one proprietary-sounding mechanism (“dual processing”), a founder-origin story, press-logo bar, and the universal closer: “Most people who try it report the same thing: ‘I wish I had done this sooner.’”
• Price outrage, the honest version. MDHearing: “Clinics can charge over $5,000 for similarly featured hearing aids… we removed the middlemen.” They answer the skeptic head-on in the FAQ: “How are our prices so low?” (The conspiracy version — Oricle’s “Big Pharma’s $5,000 scam” — converts too, and is exactly what state attorneys-general sue over. We keep the emotional beats, never the conspiracy or fake scarcity.)
• Invisibility / stigma. “What if you could hear better and no one would ever know your secret?” Our earbud aesthetic makes this angle honest for us.
• The two universal scenes: the TV-volume fight and the restaurant table. Every brand’s creative returns to them; ours should too.
• Risk reversal as CTA. “Check if you qualify for a no-risk trial” is the single most-run line in the category — qualification scarcity beats countdown timers.
• The dementia link: handle with gloves. “Hearing aids prevent dementia” is indefensible (and under Canada’s reverse-onus Competition Act, dangerous). Safe form: “untreated hearing loss is associated with cognitive decline — and hearing is one of the things researchers say you can act on.”

Formats that work on 55–75 buyers

• Long-copy advertorials on native networks and seniors’ publications — short paragraphs, bolded payoff lines, an image every 3–4 paragraphs with captions that re-sell.
• Quiz funnels feeding a phone consult (the hear.com machine, above).
• Direct mail is alive and primary — an entire vendor ecosystem exists just for hearing mailers; 55+ homeowner targeting in clinic catchments. HearingLife Canada’s print ad is the compliant local skeleton: offer + free assessment + service bundle + return policy + tracking code + disclaimer block.
• Video: first-3-second hooks that recur — the price question, the mishearing gag, the whisper demo, senior-creator unboxing UGC. 15s/30s cuts; video beat statics on cost per enquiry in 55+ campaigns.

Offer architecture

Patterns: 45 days is the floor. Per-month framing appears above ~$300. Bundles are service-based, never accessory-based. The strongest urgency device is qualification scarcity, not countdowns.

Red lines (they sued people for this)

• Eargo paid the DOJ $34.4M for unsupported diagnosis codes on insurance claims. Never imply diagnoses or coverage we can’t clinically support.
• Vermont AG v. Nano: implying FDA approval (OTC devices are only registered), fake “hearing tests” that always recommend the priciest product, perpetual sales, undisclosed terms voiding returns. All of it settled for six figures; regulators are actively hunting this category.
• Canadian overlays: the Ordinary Selling Price rules make US-style perpetual “reg. $999 now $397” pricing illegal unless the regular price was genuinely charged; performance claims need adequate testing before they run (reverse onus); “FDA registered” means nothing here. Keep the narratives, drop the fake anchors.

TranslationWhat we take from all of this

• Lead with Cearvol’s US credentials. CES 2026 innovation awards, HearAdvisor “A” lab score, HearingTracker Best Earbud 2026 — third-party proof a clinic can show a skeptical patient. This goes on every sell sheet.
• Lead the clinic pitch with the anti-cannibalization receipts: 1% of units, 66% of returners upgrading, 93% still choosing premium, optometry’s 45% walkout. “Capture rate” becomes the KPI we give clinics.
• Ship the workflow, not a box: counseling script, comparison tri-fold (entry tier vs prescription), waiting-room materials, front-desk training, 15-minute dispensing. The clinic’s effort must round to zero.
• Survivor-grade trust package: 60–90 day trial (out-signal the category’s 45), 3-year warranty with fast swap-through-the-clinic, protection-plan option for recurring revenue — and honest fixed pricing, never perpetual fake sales.
• Territory exclusivity + MAP in writing — the professional-exclusive model where “not available online” is the pitch itself. This is also exactly what we must extract contractually from UNICE.
• De-risk app-dependence: clinics must be able to fit and adjust devices without any consumer app — the LXE wind-down made “will they exist in 3 years” a question every buyer asks. Local stock, local warranty, a named rep.
• Exploit the Apple gap now. The provincial rules blocking Apple are the same rules that make clinics the mandatory front door. That moat is temporary; the window to lock in clinic relationships is while it holds.